Last reviewed · How we verify
placebo to aprepitant
Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist.
Aprepitant is a substance P/neurokinin 1 (NK1) receptor antagonist. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV), Prevention of postoperative nausea and vomiting (PONV).
At a glance
| Generic name | placebo to aprepitant |
|---|---|
| Also known as | Matching placebo to aprepritant was administered as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia. |
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | NK1 receptor antagonist |
| Target | NK1 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Aprepitant works by blocking the action of substance P, a natural substance that causes nausea and vomiting. By blocking substance P, aprepitant reduces the frequency and severity of nausea and vomiting associated with chemotherapy and radiation therapy.
Approved indications
- Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
- Prevention of postoperative nausea and vomiting (PONV)
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
- Dizziness
Key clinical trials
- Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3 (PHASE4)
- Adding Aprepitant to a Multimodal Strategy for the Prevention of Postoperative Nausea and Vomiting in High-risk Outpatient Surgical Patients (PHASE3)
- Effect of Aprepitant on Post-operative Nausea and Vomiting in Otologic Surgery (PHASE4)
- Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting (PHASE3)
- Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy (PHASE3)
- Triple Therapy of Dexamethasone, Palonosetron, and Fosaprepitant As PONV Prevention (NA)
- Aprepitant Treatment to Prevent Postoperative Nausea and Vomiting in Children Undergoing Scoliosis Surgery (PHASE2)
- Dual-dose Aprepitant to Reduce Postoperative Nausea and Vomiting After Laparoscopic Bariatric Surgery. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |